University of Antwerp, Antwerp, Belgium.
University of Ghent, Ghent, Belgium.
J Neurovirol. 2021 Dec;27(6):954-959. doi: 10.1007/s13365-021-01022-7. Epub 2021 Nov 4.
In 2020 the world was captivated by the COVID-19 pandemic. Current scientific evidence suggests an interaction of SARS-CoV-2 and the human immune system. Multiple cases were reported of patients with COVID-19 presenting with encephalopathy, confusion or agitation, stroke, and other neurologic symptoms. We present a case of a 40-year-old man diagnosed with Susac syndrome after COVID-19, presenting with acute sensorineural hearing loss, encephalopathy, a splenial "snowball-like" lesion, and branch retinal artery occlusions with distal arterial wall hyperintensity. Although the pathophysiology of Susac syndrome remains unclear, this case is in line with the ongoing debate about the influence of SARS-CoV-2 on the human immune system. Corticosteroid treatment was initiated, followed by two treatments with rituximab, with clinical improvement of the symptomatology. Maintenance treatment currently consists of mycophenolic acid (MPA). Future research will need to focus on the underlying mechanisms for COVID-19-associated (autoimmune) complications.
2020 年,全世界都被 COVID-19 大流行所吸引。目前的科学证据表明,SARS-CoV-2 与人体免疫系统相互作用。有报道称,许多 COVID-19 患者出现脑病、意识混乱或激越、中风和其他神经系统症状。我们报告了一例 COVID-19 后诊断为 Susac 综合征的 40 岁男性,表现为急性感觉神经性听力损失、脑病、胼胝体“雪球样”病变和分支视网膜动脉闭塞伴远端动脉壁高信号。尽管 Susac 综合征的病理生理学仍不清楚,但该病例符合关于 SARS-CoV-2 对人体免疫系统影响的持续争论。我们开始使用皮质类固醇治疗,随后进行了两次利妥昔单抗治疗,症状得到了改善。目前维持治疗为使用吗替麦考酚酯(MPA)。未来的研究需要集中在 COVID-19 相关(自身免疫)并发症的潜在机制上。